Investigation of factors related to N-terminal pro-B type natriuretic peptide levels in hemodialysis patients; a single center study

Abstract

Introduction: Introduction: N-terminal pro-B type natriuretic peptide (NT-proBNP) can be used to diagnose cardiac and renal disease. The association of NT-pro BNP with demographic, clinical and biochemical factors in hemodialysis is unclear. Objectives: This study aimed to examine association of NT-pro BNP and mentioned factors in hemodialysis patients. Patients and Methods: This study was conducted on 78 end-stage renal disease (ESRD) patients under hemodialysis. Demographic data, lipid profile and electrolytes were recorded. NT-proBNP was checked simultaneously and its association with mentioned factors were assessed. Results: The average NT-pro BNP level was 890.52±700.87 pg/mL (range: 0.1-3343 pg/mL). Serum level of NT-pro BNP was statistically in association with total cholesterol (P=0.002; r=-0.348), low density lipoprotein (LDL) (P=0.09; r= -0.292), high density lipoprotein (HDL) (P=0.06; r=-0.310) and serum triglyceride (P=0.018; r=-0.269) while having a direct relationship with serum ferritin (P=0.022; r=0.274), alkaline phosphatase (ALP) (P=0.048; r=0.224) and duration of hemodialysis (P=0.005; r=0.321). Conclusion: Lipid profile and ferritin are associated with NT-pro BNP levels. This can reflect possible prognostic role of NT-proBNP among ESRD patients on hemodialysis.

Clinical significance of NT-proBNP levels in Chronic Kidney Disease Patients with or without Heart Failure: An Indian Perspective

“…Approximately 30% of patients with diabetes mellitus (DM) have diabetic nephropathy and with the growing number of DM patients and aging population, there can be a parallel increase in the incidence of CKD [3]. Several studies show that patients with CKD also have a higher prevalence of left ventricular (LV) hypertrophy, ischemic heart disease (IHD), cardiac arrhythmias and valvular calcification, leading to heart failure (HF) with a preserved LV ejection fraction (HFpEF), than in the general population [4][5][6][7]. This risk increases up to 10 to 100 fold when a patient begins dialysis [8].…”